We are delighted to inform that our ongoing manufacturing partnership with BioResearch Pharma (BRP), supporting the development and production of BRP-007 (psoriasis), moved to the next phase of the technical batch production. BRP is a company developing novel topical dermatological therapies based on repurposing of known and market-authorized active substances.
The collaboration between companies covers clinical batches production of BRP-007, topical formulation for prospective, randomized, double-blind, placebo-controlled, ascending-dose Phase I study.
BRP demonstrated that use of BRP-007 resulted in improvement in patients with psoriasis. BRP-007 with its unique mechanism of action, holds blockbuster potential, as confirmed by independent research.
Around the world, some 1-3% of the population live with various forms of psoriasis. The area covered by the BRP-007 patent has a population of about 10-30 million people.
